1-4 of 4
Claudine Chollet
Close
Sort by
Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 664.
https://doi.org/10.1182/blood-2019-125108
Published: 2019
Journal Articles

A Single Nucleotide Polymorphism in Pro-Apoptotique Protein BIM Affects Chronic Myeloid Leukaemia Evolution during Imatinib Treatment

Vanessa Augis, Francis Belloc, Kelly Airiau, Claudine Chollet, Francois-Xavier Mahon
Journal: Blood
Blood (2008) 112 (11): 4227.
https://doi.org/10.1182/blood.V112.11.4227.4227
Published: 2008
Journal Articles

Defensine Alpha1 as a New Marker of Imatinib Resistance in Chronic Myelogenous Leukemia

Gabriel Etienne, Maryse Dupouy, Claudine Chollet, Jean-Max Pasquet, Eric Lippert, Josy Reiffers, François- Xavier Mahon, Beatrice Turcq
Journal: Blood
Blood (2008) 112 (11): 3180.
https://doi.org/10.1182/blood.V112.11.3180.3180
Published: 2008
Journal Articles

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

François-Xavier Mahon, Francis Belloc, Valérie Lagarde, Claudine Chollet, François Moreau-Gaudry, Josy Reiffers, John M. Goldman, Junia V. Melo
Journal: Blood
Blood (2003) 101 (6): 2368–2373.
https://doi.org/10.1182/blood.V101.6.2368
Published: 2003